# Efficacy and Safety of DWC202404 and DWC202314 in Patients With Hypertension

Study · id `cardio:ct-nct06682000` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06682000](<https://clinicaltrials.gov/study/NCT06682000>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06682000

Browse, organ or system: Blood vessels  
Browse, condition area: High blood pressure  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 192 participants.

## Technical summary

Registry record NCT06682000. Randomized; double masking; primary purpose treatment. Start 2025-01-20 (actual); primary completion 2025-10-02 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 192 participants (enrolled count; ClinicalTrials.gov record NCT06682000, source copy `cardio:ctgov-nct06682000-2026-05-08`, retrieved 2026-10-26)
- Started: 2025-01-20 (actual) (ClinicalTrials.gov record NCT06682000, source copy `cardio:ctgov-nct06682000-2026-05-08`, retrieved 2026-10-26)
- Primary completion: 2025-10-02 (actual) (ClinicalTrials.gov record NCT06682000, source copy `cardio:ctgov-nct06682000-2026-05-08`, retrieved 2026-10-26)
- Completion: 2025-10-02 (actual) (ClinicalTrials.gov record NCT06682000, source copy `cardio:ctgov-nct06682000-2026-05-08`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT06682000, source copy `cardio:ctgov-nct06682000-2026-05-08`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06682000-2026-05-08`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of DWC202404 and DWC202314 in Patients With Hypertension
- Condition: Hypertension
- Condition: Essential Hypertension
- Intervention (Drug): DWC202404, DWC202314
- Intervention (Drug): DWC202404, DWC202314P
- Lead sponsor: Daewoong Pharmaceutical Co. LTD.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Hypertension (high blood pressure) (`core:hypertension`)
- Registry lists this organization as the lead sponsor: Daewoong Pharmaceutical Co. LTD. (`cardio:org-daewoong-pharmaceutical-co-ltd`)

## Provenance

Content hash: 5fb9d307974cb1408deecf2f2e6e8f9b0bf703717338b783d54f036a98f3b42d
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
